Media stories about Crispr Therapeutics (NASDAQ:CRSP) have trended somewhat positive on Thursday, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Crispr Therapeutics earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave headlines about the company an impact score of 43.4050752838191 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news headlines that may have impacted Accern Sentiment’s scoring:
Several research analysts have recently issued reports on the company. Piper Jaffray Companies reissued a “buy” rating and issued a $22.75 price target (down previously from $39.00) on shares of Crispr Therapeutics in a research note on Wednesday. Oppenheimer reaffirmed a “hold” rating on shares of Crispr Therapeutics in a research note on Thursday, December 21st. SunTrust Banks reaffirmed a “hold” rating and set a $16.00 target price on shares of Crispr Therapeutics in a research note on Friday, November 10th. Cann reaffirmed a “hold” rating on shares of Crispr Therapeutics in a research note on Thursday, November 9th. Finally, BidaskClub raised Crispr Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, January 4th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $22.81.
Crispr Therapeutics (CRSP) opened at $25.77 on Thursday. Crispr Therapeutics has a 52 week low of $11.63 and a 52 week high of $28.50. The firm has a market capitalization of $1,060.00 and a PE ratio of -80.53.
Crispr Therapeutics (NASDAQ:CRSP) last announced its earnings results on Wednesday, November 8th. The company reported ($0.62) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.02). Crispr Therapeutics had a negative net margin of 466.58% and a negative return on equity of 38.42%. The firm had revenue of $2.39 million for the quarter, compared to the consensus estimate of $3.61 million. During the same period in the prior year, the business earned ($2.77) EPS. The company’s quarterly revenue was up 54.2% compared to the same quarter last year. sell-side analysts predict that Crispr Therapeutics will post -2.46 earnings per share for the current fiscal year.
In related news, major shareholder Corp /De/ Celgene sold 10,000 shares of the firm’s stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $17.28, for a total transaction of $172,800.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Thomas Woiwode sold 1,700 shares of the firm’s stock in a transaction dated Friday, November 24th. The shares were sold at an average price of $20.21, for a total value of $34,357.00. Following the transaction, the director now directly owns 8,218 shares of the company’s stock, valued at approximately $166,085.78. The disclosure for this sale can be found here. Insiders have sold 2,168,504 shares of company stock valued at $42,538,573 in the last ninety days. Company insiders own 39.98% of the company’s stock.
About Crispr Therapeutics
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for Crispr Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Crispr Therapeutics and related companies with our FREE daily email newsletter.